A new generation of CRISPR technology developed at UNSW Sydney offers a safer path to treating genetic diseases like sickle ...

CRISPR Therapeutics advances with promising CTX310 data and key clinical milestones ahead. Click here to read an analysis of ...

A study has revealed that chemical tags once regarded as genetic clutter are in fact powerful gene silencers – and removing ...

A man with type 1 diabetes has become the first patient to produce his own insulin after receiving genetically engineered cell transplants, without needing drugs to prevent rejection.

We expect investors to focus on the sales performance of CRISPR Therapeutics’ CRSP sole-marketed product, Casgevy, and other pipeline updates when the company reports its second-quarter 2025 results.

In the past two years, a spate of technological advances and promising results in mice have been laying the groundwork for ...

Tiny "hidden" proteins lurking in DNA once dismissed as junk may hold the key to the next generation of obesity drugs, ...

There could be new hope for people aiming to fight obesity following a research breakthrough identifying certain microproteins that store fat.In findings published in the Proceedings of the National ...

The multiagent AI system, dubbed “CRISPR-GPT,” is designed to interact and reason with human users as they execute gene-editing tasks. The model was trained using data from scientific literature, ...

Clustered regularly interspaced short palindromic repeats (CRISPR)-based therapeutics are rapidly gaining traction for the management of infectious diseases. Programs targeting pathogens such as the ...

Mars partners with Pairwise to use CRISPR tech for developing disease- and climate-resilient cacao, aiming to secure future ...

CRISPR Therapeutics (CRSP) recently announced significant developments in its in vivo cardiovascular disease programs, notably CTX310 and CTX320, which may have contributed to the company's 47% share ...